Roots Analysis is pleased to announce the publication of its recent study, titled, “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market, 2021-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.”
Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access
Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.
The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:
Browse Detailed Report: https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html